Europe’s Chemical Industry in the Ice Age: Profits Evaporating, Plants Shutting Down, Capital Fleeing—A Systemic Collapse Is Underway

In the deep autumn of 2025, as northern European winds sweep along the Rhine, the continent’s chemical giants are enduring a chill far more biting than winter itself. Third-quarter earnings reports have fallen like snowflakes—not as harvest celebrations, but as distress signals from the industrial frontlines: BASF’s profits halved, Bayer mired in litigation, Evonik swinging to a net loss, Covestro’s plant burned to a halt, and AkzoNobel slashing its full-year guidance. The entire European chemical sector appears to have hit a collective “stall button.”

This is not a cyclical dip—it is the prelude to a structural collapse. Overcapacity, price wars, currency volatility, persistently high energy costs, and supply chains fractured by geopolitics have converged into a perfect storm. In just a few years, Europe’s once-dominant chemical empire has slid from a “technology high ground” into a “profitability sinkhole.” The irony? While struggling at home, BASF’s Zhanjiang mega-site in China glows with activity—poised to become its sole beacon of hope for 2026–2027.

Profits aren’t just declining—they’re evaporating. Flip through the Q3 reports, and the most alarming phrase isn’t “year-over-year decline,” but “swung to a net loss.” Evonik reported a net loss of €106 million, ostensibly due to restructuring and asset impairments in its Infrastructure segment. But the real story lies beneath: core businesses are faltering. Revenue dropped 12%, and margins slid from 15.1% to 13.2%—a seemingly small shift that, across billions in sales, translates into a hundred-billion-euro-scale profit black hole.

Covestro’s saga is even more dramatic: an off-site fire triggered a power outage, crippling its 280,000-ton-per-year TDI (toluene diisocyanate) plant in Dormagen, Germany, and causing direct losses of €150 million. TDI is essential for polyurethane foams used in mattresses, car seats, and insulation. Once a global flagship facility, it is now synonymous with “force majeure.” Yet despite this catastrophe, Covestro’s EBITDA still beat expectations—precisely because markets no longer expect “normal operations” from European chemical firms; merely avoiding total collapse now counts as good news.

Lanxess reveals an even deeper fracture: its High Performance Materials segment saw profits plunge by 61.8%, while its Specialty Additives business fell 26.2% amid weak demand and underutilized capacity. Only its Consumer Protection segment held firm, with EBITDA up 1.4%. This tells a stark truth: Europe’s halo of high-end manufacturing is fading—only low-value, essential products still offer breathing room.

European chemical companies are caught in a vise. On one side, global overcapacity has triggered a price collapse—new plants in China, the U.S., and the Middle East keep flooding the market, especially in base chemicals, turning pricing into a bloodbath. On the other, soaring domestic energy and labor costs remain entrenched. Even though natural gas prices have retreated from 2022 peaks, European industrial electricity rates are still 2–3 times higher than in the U.S. and 4 times China’s.

BASF embodies this dilemma. Europe’s chemical titan posted dual declines in sales and profit, with Jefferies bluntly stating in its November 11 report that “nearly all metrics are at cyclical lows.” Worse, 2025 will bring heavy capital expenditures—but not for expansion in Ludwigshafen. Instead, the money flows to its integrated Verbund site in Zhanjiang, China, a €10+ billion project set to become BASF’s primary growth engine for the next decade. The bitter irony? The lifeline for Europe’s flagship chemical company comes from the very market it once sought to “de-risk” from.

Behind the numbers lies a collapse of confidence. AkzoNobel, Arkema, and Covestro have all downgraded full-year EBITDA guidance—not out of caution, but admission: weak demand, intensifying competition, and relentless price pressure are unsolvable in the near term.

Take Arkema: though slightly beating expectations, it slashed its annual EBITDA target to €1.25–1.3 billion, citing “disappointing U.S. demand.” The U.S. was supposed to be Europe’s last safe harbor—now even that refuge is crumbling. AkzoNobel, meanwhile, managed to stabilize EBITDA through “structural cost control,” but falling sales and revised guidance expose the fragility of its coatings business amid a global property slump.

Only Bayer offered a flicker of light: its Crop Science division saw adjusted EBITDA double to €172 million, with margins jumping from 0.9% to 4.5%. Yet this glow is drowned by the shadow of litigation—its glyphosate lawsuits remain unresolved, dragging the company into another quarterly net loss. Technology can generate profits, but legacy liabilities can sink an empire.

This isn’t just about bad quarters—it’s about Europe’s marginalization in a reshaped global order. For two decades, European chemical firms ruled through technological moats, environmental standards, and brand premium. Today, that edge is eroding:

• China leverages full-chain integration and scale to dominate base chemicals with “cost crushing”;
• The U.S. exploits shale gas to build low-cost olefin derivatives clusters;
• The Middle East uses sovereign capital to pivot from fuel exporter to advanced materials supplier.

And Europe? Trapped in a “triple-high trap”—high costs, high regulation, low growth—it can neither wage price wars nor innovate fast enough. When Covestro’s TDI plant burns down, it takes months to restart; Chinese peers can relaunch in 30 days. That’s the efficiency chasm.

Even more telling is the shift in capital flows. Global investors are fleeing traditional European chemical stocks. As Jefferies’ bearish stance shows, money is rotating into new frontiers—battery materials, electronic chemicals, bio-based polymers—where Europe no longer holds a decisive lead, and China is already ahead in pockets.

Amid this gloom, BASF’s Zhanjiang project stands as a rare spark of hope. Fully owned by BASF, this integrated site bypasses joint-venture restrictions and serves Asia-Pacific’s booming EV, electronics, and consumer markets directly. Crucially, it enables “Chinese-cost production with European-quality standards”—a hybrid advantage impossible at home.

This may define Europe’s future path: abandon dreams of continental revival and embed high-value capacity inside growth markets via “enclave models”. Evonik, Covestro, and Lanxess have begun similar moves in China—but none with BASF’s boldness.

This isn’t just winter coming—it’s the climate changing. Europe’s Q3 chemical carnage marks the end of an era: the time when technological superiority, regional barriers, and energy rents guaranteed global dominance is over.

Today’s battlefield rewards not who has the fancier lab, but who runs the leanest cost curve, the most resilient supply chain, and the fastest response cycle. In this new race, Europe started half a lap behind.

If it clings to the illusion that “high quality always commands premium pricing” and refuses to accept global pricing realities, then today’s profit evaporation is merely the prologue to a far larger industrial exodus. After all, in the ruthless logic of capital and markets, nostalgia won’t restart a plant, and historical glory won’t satisfy shareholders.

What Europe’s chemical industry needs isn’t more cost-cutting—it’s a total self-reinvention. Otherwise, this Ice Age may have no spring.